Gary Mo

518 total citations
21 papers, 153 citations indexed

About

Gary Mo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gary Mo has authored 21 papers receiving a total of 153 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Gary Mo's work include Sarcoma Diagnosis and Treatment (7 papers), Vascular Tumors and Angiosarcomas (5 papers) and Statistical Methods in Clinical Trials (3 papers). Gary Mo is often cited by papers focused on Sarcoma Diagnosis and Treatment (7 papers), Vascular Tumors and Angiosarcomas (5 papers) and Statistical Methods in Clinical Trials (3 papers). Gary Mo collaborates with scholars based in United States, Spain and United Kingdom. Gary Mo's co-authors include Wojciech Krzyżański, Ilaria Conti, Robin L. Jones, William D. Tap, Damien M. Cronier, Robert Ilaria, Robert J. Bauer, John R. Baldwin, Debra Luffer‐Atlas and Michael Heathman and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Gary Mo

18 papers receiving 150 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Mo United States	8	69	68	28	20	19	21	153
Stefanie Kraff Germany	8	40 0.6×	144 2.1×	27 1.0×	18 0.9×	18 0.9×	15	271
N. Varol United Kingdom	7	76 1.1×	89 1.3×	57 2.0×	22 1.1×	6 0.3×	26	294
Narayanan Srihari United Kingdom	5	69 1.0×	47 0.7×	36 1.3×	48 2.4×	8 0.4×	8	128
Jennie Chang United States	4	45 0.7×	161 2.4×	50 1.8×	37 1.9×	22 1.2×	4	339
Arthur Géraud France	9	114 1.7×	150 2.2×	53 1.9×	41 2.0×	19 1.0×	25	277
Marjorie Baciuchka France	7	70 1.0×	51 0.8×	49 1.8×	40 2.0×	7 0.4×	14	158
Anees M. Dauki United States	8	25 0.4×	53 0.8×	99 3.5×	40 2.0×	14 0.7×	15	258
Pongwut Danchaivijitr Thailand	9	137 2.0×	123 1.8×	36 1.3×	29 1.4×	9 0.5×	33	258
Jan Meiners Germany	5	29 0.4×	25 0.4×	59 2.1×	36 1.8×	19 1.0×	7	165

Countries citing papers authored by Gary Mo

Since Specialization

Citations

This map shows the geographic impact of Gary Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Mo more than expected).

Fields of papers citing papers by Gary Mo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Mo. The network helps show where Gary Mo may publish in the future.

Co-authorship network of co-authors of Gary Mo

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Mo. A scholar is included among the top collaborators of Gary Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Mo. Gary Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gao, Xin, Yanming Huang, Tai Wei, et al.. (2025). TFAP2A-regulated CRNDE enhances colon cancer progression and chemoresistance via RIPK3 interaction. Functional & Integrative Genomics. 25(1). 36–36. 1 indexed citations

Lou, Shenghan, Hao Wang, Gary Mo, et al.. (2025). A TRIM21–UCHL3–ITCH–SIPA1 axis promotes colorectal cancer growth and metastasis. Cancer Letters. 639. 218221–218221.

Lou, Shenghan, Yanming Huang, Jianxin Xue, et al.. (2025). Development and validation of a deep learning-based pathomics signature for prognosis and chemotherapy benefits in colorectal cancer: a retrospective multicenter cohort study. Frontiers in Immunology. 16. 1602909–1602909. 1 indexed citations

Lou, Shenghan, Huiying Li, Yanming Huang, et al.. (2025). Development and validation of a deep learning–based pathomics signature for prognosis and chemotherapy benefits in colorectal cancer: A retrospective multicenter cohort study.. Journal of Clinical Oncology. 43(4_suppl). 298–298.

Shahin, Mohamed H., Prashant Desai, Nadia Terranova, et al.. (2025). AI‐Driven Applications in Clinical Pharmacology and Translational Science: Insights From the ASCPT 2024 AI Preconference. Clinical and Translational Science. 18(4). e70203–e70203. 6 indexed citations

Lu, James, Keunwoo Choi, Jogarao Gobburu, et al.. (2025). Large Language Models and Their Applications in Drug Discovery and Development: A Primer. Clinical and Translational Science. 18(4). e70205–e70205. 5 indexed citations

Mascarenhas, Leo, Chitose Ogawa, Theodore W. Laetsch, et al.. (2021). Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer Medicine. 10(3). 843–856. 2 indexed citations

Martín‐Broto, Javier, Antonio López–Pousa, Andrew S. Brohl, et al.. (2020). Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Molecular Cancer Therapeutics. 20(1). 132–141. 9 indexed citations

Villalobos, Víctor M., Gary Mo, Mark Agulnik, et al.. (2019). Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma. Cancer Medicine. 9(3). 882–893. 2 indexed citations

10.

Pelzer, Uwe, Johanna C. Bendell, Mark Womack, et al.. (2019). A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology. 37(4_suppl). 330–330. 2 indexed citations

11.

Brooks, Nathan A., Lisa Kays, John Strelow, et al.. (2019). Abstract LB-274: Identification and characterization of LY3410738, a novel covalent inhibitor of cancer-associated mutant Isocitrate Dehydrogenase 1 (IDH1). Cancer Research. 79(13_Supplement). LB–274. 9 indexed citations

12.

Jones, Robin L., Gary Mo, John R. Baldwin, et al.. (2018). Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma. Cancer Chemotherapy and Pharmacology. 83(1). 191–199. 9 indexed citations

13.

Parra‐Guillén, Zinnia P., Víctor Mangas‐Sanjuán, Maria Garcia‐Cremades, et al.. (2018). Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts. Journal of Pharmacology and Experimental Therapeutics. 366(1). 96–104. 8 indexed citations

14.

DuBois, Steven G., Brenda J. Weigel, Theodore W. Laetsch, et al.. (2018). Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.. Journal of Clinical Oncology. 36(15_suppl). 10541–10541.

15.

Mo, Gary, John R. Baldwin, Debra Luffer‐Atlas, et al.. (2017). Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer. Clinical Pharmacokinetics. 57(3). 355–365. 21 indexed citations

16.

Redondo, Andrés, Nadia Hindi, José A. López-Martín, et al.. (2016). ANNOUNCE 2: An open-label phase 1b, and a randomized, double-blind phase 2 study of olaratumab with gemcitabine plus docetaxel in the treatment of patients with advanced soft tissue sarcoma (STS). Annals of Oncology. 27. vi491–vi491. 1 indexed citations

17.

Jones, Robin L., Gary Mo, John R. Baldwin, et al.. (2016). Exposure-response of olaratumab for survival outcomes and safety when combined with doxorubicin in soft tissue sarcoma (STS) patients. Annals of Oncology. 27. vi485–vi485. 1 indexed citations

18.

Mo, Gary, et al.. (2014). Lifespan Based Pharmacokinetic-Pharmacodynamic Model of Tumor Growth Inhibition by Anticancer Therapeutics. PLoS ONE. 9(10). e109747–e109747. 6 indexed citations

19.

Perera, Vidya, Robert R. Bies, Gary Mo, et al.. (2014). Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. British Journal of Clinical Pharmacology. 78(4). 800–814. 12 indexed citations

20.

Bauer, Robert J., Gary Mo, & Wojciech Krzyżański. (2013). Solving delay differential equations in S-ADAPT by method of steps. Computer Methods and Programs in Biomedicine. 111(3). 715–734. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact